TENX (Tenax Therapeutics) Short Interest


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $12.89
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TENX vs RZLT, PRLD, NAGE: Short Interest Comparison

For the Biotechnology subindustry, Tenax Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Short Interest falls into.


TENX
22GF Score
Tenax Therapeutics Inc TENX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.89
Price